Summary
Global Markets Direct’s, ‘Ipsen S.A. - Product Pipeline Review - 2016’, provides an overview of the Ipsen S.A.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Ipsen S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Ipsen S.A.
- The report provides overview of Ipsen S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ipsen S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ipsen S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Ipsen S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ipsen S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ipsen S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Ipsen S.A. Snapshot 7
Ipsen S.A. Overview 7
Key Information 7
Key Facts 7
Ipsen S.A. - Research and Development Overview 8
Key Therapeutic Areas 8
Ipsen S.A. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Ipsen S.A. - Pipeline Products Glance 17
Ipsen S.A. - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Ipsen S.A. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Phase 0 Products/Combination Treatment Modalities 21
Ipsen S.A. - Early Stage Pipeline Products 22
Preclinical Products/Combination Treatment Modalities 22
Discovery Products/Combination Treatment Modalities 23
Ipsen S.A. - Drug Profiles 24
lanreotide acetate 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
abobotulinumtoxin A 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
abobotulinumtoxin A next generation 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
triptorelin pamoate PR 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BN-82451 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BIM-23A758 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
3BP-227 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Peptides for Endocrine Gland Disorders 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Peptides for Oncology and Genito Urinary System And Sex Hormones 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Peptides to Antagonize ACTH Receptor for Cushing's Syndrome 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Protein 1 to Inhibit SNARE for Neurology 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Recombinant Protein 1 to Target SNAP-25 for Movement Disorders 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Recombinant Protein 2 to Inhibit SNARE for Neurology 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Recombinant Protein 3 to Target SNAP-25 for Movement Disorders 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
STX-140 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
STX-681 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SXN-101742 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SXN-101959 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Drugs to Antagonize Androgen Receptor for Prostate Cancer 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Peptides for Endocrine Disease 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Recombinant Protein 2 to Target SNAP-25 for Movement Disorders 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Recombinant Protein 4 to Target SNAP-25 for Movement Disorders 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Ipsen S.A. - Pipeline Analysis 49
Ipsen S.A. - Pipeline Products by Target 49
Ipsen S.A. - Pipeline Products by Route of Administration 51
Ipsen S.A. - Pipeline Products by Molecule Type 52
Ipsen S.A. - Pipeline Products by Mechanism of Action 53
Ipsen S.A. - Recent Pipeline Updates 54
Ipsen S.A. - Dormant Projects 61
Ipsen S.A. - Discontinued Pipeline Products 62
Discontinued Pipeline Product Profiles 62
BIM-23A760 62
(mecasermin + somatropin) 62
irosustat 62
taspoglutide 62
Ipsen S.A. - Company Statement 63
Ipsen S.A. - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68
List of Tables
Ipsen S.A., Key Information 7
Ipsen S.A., Key Facts 7
Ipsen S.A. - Pipeline by Indication, 2016 9
Ipsen S.A. - Pipeline by Stage of Development, 2016 11
Ipsen S.A. - Monotherapy Products in Pipeline, 2016 12
Ipsen S.A. - Partnered Products in Pipeline, 2016 13
Ipsen S.A. - Partnered Products/ Combination Treatment Modalities, 2016 14
Ipsen S.A. - Out-Licensed Products in Pipeline, 2016 15
Ipsen S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Ipsen S.A. - Pre-Registration, 2016 17
Ipsen S.A. - Phase III, 2016 18
Ipsen S.A. - Phase II, 2016 19
Ipsen S.A. - Phase I, 2016 20
Ipsen S.A. - Phase 0, 2016 21
Ipsen S.A. - Preclinical, 2016 22
Ipsen S.A. - Discovery, 2016 23
Ipsen S.A. - Pipeline by Target, 2016 49
Ipsen S.A. - Pipeline by Route of Administration, 2016 51
Ipsen S.A. - Pipeline by Molecule Type, 2016 52
Ipsen S.A. - Pipeline Products by Mechanism of Action, 2016 53
Ipsen S.A. - Recent Pipeline Updates, 2016 54
Ipsen S.A. - Dormant Developmental Projects,2016 61
Ipsen S.A. - Discontinued Pipeline Products, 2016 62
Ipsen S.A., Subsidiaries 64
List of Figures
Ipsen S.A. - Pipeline by Top 10 Indication, 2016 9
Ipsen S.A. - Pipeline by Stage of Development, 2016 11
Ipsen S.A. - Monotherapy Products in Pipeline, 2016 12
Ipsen S.A. - Partnered Products in Pipeline, 2016 13
Ipsen S.A. - Out-Licensed Products in Pipeline, 2016 15
Ipsen S.A. - Pipeline by Top 10 Target, 2016 49
Ipsen S.A. - Pipeline by Route of Administration, 2016 51
Ipsen S.A. - Pipeline by Molecule Type, 2016 52
Ipsen S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016 53
